Second-line systemic therapy for the treatment of metastatic renal cell cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Molecular mechanisms of renal cell carcinoma (RCC) progression have enabled targeted drug development.
• VEGF-targeting pathway inhibition is a successful first-line treatment for metastatic RCC.
• Current first-line treatments include bevacizumab/IFN-α, sunitinib, pazopanib, and temsirolimus, depending on patient risk stratification.

Purpose of the Study:

• To review and identify the best second-line treatment options for patients with metastatic RCC who progress after first-line therapy.
• To evaluate sequential therapy strategies, including tyrosine kinase inhibitor (TKI)-mTOR inhibitor and TKI-TKI sequences.
• To determine the optimal choice between sequential TKIs or VEGF followed by mTOR inhibition for specific patient populations.

Main Methods:

• Literature review of clinical trials and treatment guidelines for metastatic RCC.
• Analysis of efficacy and safety data for various second-line treatment sequences.
• Comparison of TKI-mTOR inhibitor versus TKI-TKI sequential therapies.

Main Results:

• Second-line treatment options are crucial as patients with metastatic RCC eventually progress.
• Sequential therapies involving TKIs, mTOR inhibitors, or combinations are being investigated.
• The optimal sequence of TKIs or the combination of VEGF inhibition followed by mTOR inhibition requires further clarification for specific patient groups.

Conclusions:

• Identifying the most beneficial second-line treatment sequence is critical for managing advanced RCC.
• Further research is needed to establish definitive evidence-based guidelines for sequential therapy in metastatic RCC.
• Personalized treatment strategies considering patient risk and prior therapy are essential for optimizing outcomes.